Clinical trialPhase 1 / Phase 2Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 14 November 2023
- Expected end
- November 2027
- Enrollment
- 255 participants
- Sites
- 5
- Primary outcomes
- Dose Escalation part: Dose Limiting Toxicities (DLTs); Dose Escalation part: treatment emergent adverse events (TEAEs); Dose Escalation part: clinically significant changes in Leucocytes count; Dose Escalation part: clinically significant changes in Red Blood Cells Count; Dose Escalation part: clinically significant changes in Hemoglobin
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 20 August 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D.